Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory

We came crossed a bullish thesis connected Axsome Therapeutics, Inc. connected X.com by @MoneyShow. In this article, we volition summarize the bulls’ thesis connected AXSM. Axsome Therapeutics, Inc.'s stock was trading astatine $163.19 arsenic of February 26th. AXSM’s guardant P/E was 370.37 according to Yahoo Finance.

A vessel with pills

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers caller therapies for the absorption of cardinal tense system disorders successful the United States. Axsome Therapeutics, is emerging as a differentiated neuro-focused biotech with aggregate commercialized assets and a late-stage pipeline targeting large, underserved markets. Unlike galore single-asset peers, Axsome already has 3 products connected the market, providing a diversified and rapidly expanding gross base.

Its pb product, Auvelity for large depressive disorder, is the superior maturation engine, with income rising 69% in 3rd quarter and absorption projecting highest income of roughly $2 billion—around 4 times its existent run-rate. Sunosi, indicated for sleep apnea, posted 35% maturation last quarter, while Symbravo for acute migraines has precocious launched and is expected to standard toward a $400 cardinal highest opportunity, similar to Sunosi’s long-term potential.

The pipeline further strengthens the maturation narrative. AXS-12 for narcolepsy is viewed arsenic a imaginable $500 cardinal product, portion AXS-05 for Alzheimer’s agitation, with possible approval in the archetypal fractional of 2026, could transcend $1.5 cardinal successful highest sales. Another Phase III campaigner targeting ADHD and related indications may represent an additional $1 cardinal opportunity.

Commercial momentum is already evident, with wide income rising 63% and 72% successful the past two quarters, and analysts forecasting 50%+ maturation adjacent year. While profitability remains ahead, breakeven is expected successful 2026 arsenic standard improves. After consolidating for 9 months, the banal has breached to caller highs, suggesting improving sentiment. With accelerating revenues and aggregate regulatory catalysts ahead, Axsome presents a compelling maturation communicative with meaningful upside potential.

Previously, we covered a bullish thesis on Crispr Therapeutics (CRSP) by MADD-Scientis in March 2025, which highlighted the commercialized imaginable of Casgevy, beardown nett currency position, and upside from its broader gene-editing pipeline. Crispr Therapeutics’s stock terms has appreciated by astir 50.69% since our coverage. @MoneyShow shares a akin presumption but emphasizes on Axsome’s diversified commercialized basal and accelerating gross maturation wrong neuro-focused therapeutics.